FTY720 attenuates tubulointerstitial inflammation and fibrosis in subtotally nephrectomized rats

Renal Failure

Volumn 35, Issue 7, 2013, Pages 996-1004

  Ni, Hai Feng ^a   Chen, Jun Feng ^a   Zhang, Ming Hui ^a   Pan, Ming Ming ^a   Zhang, Jian Dong ^a   Liu, Hong ^a   Tang, Ri Ning ^a   Ma, Kun Ling ^a   Liu, Bi Cheng ^a  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

Chronic kidney disease; FTY720; Inflammation; Interstitial fibrosis; Lymphocyte

Indexed keywords

CD163 ANTIGEN; CD20 ANTIBODY; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CHLORDANE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CREATININE; FIBRONECTIN; FINGOLIMOD; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; N ACETYL BETA GLUCOSAMINIDASE; NITROGEN; PLACEBO; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CELL INFILTRATION; CREATININE BLOOD LEVEL; CYTOKINE PRODUCTION; DRUG MECHANISM; ENZYME ACTIVITY; INTERSTITIAL NEPHRITIS; KIDNEY FIBROSIS; LEUKOCYTE; LYMPHOCYTE; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; RAT; UPREGULATION; UREA NITROGEN BLOOD LEVEL;

ANIMALS; CELL MOVEMENT; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; FIBROSIS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-6; KIDNEY TUBULES; LYMPHOCYTES; MALE; NEPHRECTOMY; NEPHRITIS, INTERSTITIAL; PROPYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; RENAL INSUFFICIENCY; SPHINGOSINE; TRANSFORMING GROWTH FACTOR BETA1; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84880278356     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2013.809006     Document Type: Article

References (34)

1. Eddy AA. Scraping fibrosis: UMODulating renal fibrosis. Nat Med. 2011;17:553-555.
2. Hewitson TD. Renal tubulointerstitial fibrosis: common but never simple. Am J Physiol Renal Physiol. 2009;296:F1239-F1244.
3. Liu Y, Chowdhury P, Sacks SH, Sheerin NS, Wong W. Pivotal role of CD4+ T cells in renal fibrosis following ureteric obstruction. Kidney Int. 2010;78:351-362.
4. Eardley KS, Zehnder D, Quinkler M, et al. The relationship between albuminuria, MCP-1/CCL2, and interstitial macrophages in chronic kidney disease. Kidney Int. 2006; 69(7):1189-1197.
5. López-Hernández FJ, López-Novoa JM. Role of TGF-b in chronic kidney disease: an integration of tubular, glomerular and vascular effects. Cell Tissue Res. 2012;347(1):141-154.
6. Cook HT. The origin of renal fibroblasts and progression of kidney disease. Am J Pathol. 2010; 176(1):22-24.
7. Hoitsma AJ, Woodle ES, Abramowicz D, Proot P, Vanrenterghem Y. FTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study. Nephrol Dial Transplant. 2011;26(11):3802-3805.
8. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004;427(6972):355-360.
9. Peters H, Martini S, Wang Y, et al. Selective lymphocyte inhibition by FTY720 slows the progressive course of chronic anti-thy1 glomerulosclerosis. Kidney Int. 2004;6(4):1434-1443.
10. Awad AS, Ye H, Huang L, et al. Selective sphingosine 1-phosphate 1 receptor activation reduces Ischemia-reperfusion injury in mouse kidney. Am J Physiol Renal Physiol. 2006;290(6):1516-1524.
11. Schaier M, Vorwalder S, Sommerer C, et al. Role of FTY720 on M1 and M2 macrophages, lymphocytes, and chemokines in 5/6 nephrectomized rats. Am J Physiol Renal Physiol. 2009;297(3):769-780.
12. Krämer S, Binder E, Loof T, et al. The lymphocyte migration inhibitor FTY720 attenuates experimental hypertensive nephropathy. Am J Physiol Renal Physiol. 2009;297(1):F218-F227.
13. Sui M, Zhou J, Xie R, et al. The sphingosine-1-phosphate receptor agonist FTY720 prevents the development of anti-glomerular basement membrane Glomerulonephritis. Mol Biol Rep. 2012;39(1):389-397.
14. Ji L, Masuda S, Saito H, Inui K. Down-regulation of rat organic cation transporter rOCT2 by 5/6 nephrectomy. Kidney Int 2002;62:514-524.
15. Finney CA, Hawkes CA, Kain DC, et al. S1P is associated with protection in human and experimental cerebral malarial. Mol Med. 2011;17(7-8):717-725.
16. Chen JF, Ni HF, Pan MM, et al. Pirfenidone inhibits macrophage infiltration in 5/6 nephrectomized rats. Am J Physiol Renal Physiol. 2013;304(6):F676-F685.
17. An WS, Kim HJ, Cho KH, Vaziri ND. Omega-3 fatty acid supplementation attenuates oxidative stress, inflammation, and tubulointerstitial fibrosis in the remnant kidney. Am J Physiol Renal Physiol. 2009;297(4):895-903.
18. Krämer S, Loof T, Martini S, et al. Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis, but is not additive to a high dose of enalapril. Am J Physiol Renal Physiol. 2005;289(2):F359-F368.
19. Anders HJ. Four danger response programs determine glomerular and tubulointerstitial kidney pathology: clotting, inflammation, epithelial and mesenchymal healing. Organogenesis. 2012;8(2):1-12.
20. Boor P, Sebeková K, Ostendorf T, Floege J. Treatment targets in renal fibrosis. Nephrol Dial Transplant. 2007;22(12): 3391-3407.
21. Zeisberg M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol. 2010;21(11):1819-1834.
22. Anders HJ, Ryu M. Renal microenvironments and macrophage Phenotypes determine progression or resolution of renal inflammation and fibrosis. Kidney Int. 2011;80(9):915-925.
23. Tapmeier TT, Fearn A, Brown K, et al. Pivotal role of CD4+ T cells in renal fibrosis following ureteric obstruction. Kidney Int. 2010;78(4):351-362.
24. Husby G, Tung KS, Williams Jr RC. Characterization of renal tissue lymphocytes in patients with interstitial nephritis. Am J Med. 1981;70:31-38.
25. Rosen H, Goetzl EJ. Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat Rev Immunol. 2005;5(7):560-570.
26. Singer II, Tian M, Wickham LA, et al. Sphingosine-1-phosphate agonists increase macrophage homing, lymphocyte contacts, and endothelial junctional complex formation in murine lymph nodes. J Immunol. 2005;175(11):7151-7161.
27. Eardley KS, Zehnder D, Quinkler M, et al. The relationship between albuminuria, MCP-1/CCL2, and interstitial macrophages in chronic kidney disease. Kidney Int. 2006;9(7):1189-1197.
28. Rovin BH, Lu L, Marsh CB. Lymphocytes induce monocyte chemoattractant protein1 production by renal cells after Fc gamma receptor cross-linking: role of IL-1 beta. J Leukoc Biol. 2001;69(3):435-439.
29. Ricardo SD, Van Goor H, Eddy AA. Macrophage diversity in renal injury and repair. J Clin Invest. 2008;118(11):3522-3530.
30. Lin SL, Castanõ AP, Nowlin BT, Lupher Jr ML, Duffield JS. Bone marrow Ly6Chigh monocytes are selectively recruited to injured kidney and differentiate into functionally distinct populations. J Immunol. 2009;183(10):6733-6743.
31. Badylak SF, Valentin JE, Ravindra AK, McCabe GP, Stewart- Akers AM. Macrophage phenotype as a determinant of biologic scaffold remodeling. Tissue Eng Part A. 2008;14(11):1835-1842.
32. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355(11):1124-1140.
33. Pfeilschifter W, Czech-Zechmeister B, Sujak M, Foerch C, Wichelhaus TA, Pfeilschifter J. Treatment with the immunomodulator FTY720 does not promote spontaneous bacterial infections after experimental stroke in mice. Exp Transl Stroke Med. 2011;3:2-7.
34. Johnson TA, Lapierre Y, BarOr A, Antel JP. Distinct properties of circulating CD8+ T cells in FTY720-treated patients with multiple sclerosis. Arch Neurol. 2010;67:1449-1455.